Dutch Startup CryoCloud Lands €2M to Automate Cryo-EM for Drug Discovery

by BiopharmaTrend   •     

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email   |  

Dutch startup CryoCloud, a provider of cloud-native tools for cryo-electron microscopy (cryo-EM) data analysis, has raised €2M in seed funding to further develop its automation-first SaaS platform. The round was led by Nina Capital and joined by Value Creation Capital, ROM Utrecht, and Utrecht Health Seed Fund, bringing total funding to €2.8M following a €500K pre-seed round in 2023.

CryoCloud’s platform supports high-throughput structural biology workflows, enabling users across 25+ countries (also researchers in academia, biotech, and pharma) to process large cryo-EM datasets with access to petabyte-scale storage and dozens of GPUs via a private or hybrid cloud setup. Recent developments include:

  • Cryo-ET workflow
  • Advanced data visualisation tools
  • Proprietary algorithms
  • ISO27001 certification

CEO Robert Englmeier, PhD, described the platform as the first turnkey cloud system for cryo-EM, claiming productivity gains and easier scaling of cryo-EM projects. CryoCloud leverages proprietary machine learning algorithms to analyze structural data at atomic resolution, aiming to reduce the cost, time, and hardware barriers that have historically limited adoption of cryo-EM outside of elite facilities.

Topics: Startups & Deals   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email